HUP0302053A3 - Stable salts of o-acetylsalicylic with basic amino acids amino acids - Google Patents

Stable salts of o-acetylsalicylic with basic amino acids amino acids

Info

Publication number
HUP0302053A3
HUP0302053A3 HU0302053A HUP0302053A HUP0302053A3 HU P0302053 A3 HUP0302053 A3 HU P0302053A3 HU 0302053 A HU0302053 A HU 0302053A HU P0302053 A HUP0302053 A HU P0302053A HU P0302053 A3 HUP0302053 A3 HU P0302053A3
Authority
HU
Hungary
Prior art keywords
amino acids
acetylsalicylic
stable salts
basic amino
basic
Prior art date
Application number
HU0302053A
Other languages
English (en)
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of HUP0302053A2 publication Critical patent/HUP0302053A2/hu
Publication of HUP0302053A3 publication Critical patent/HUP0302053A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
HU0302053A 2000-07-18 2001-07-05 Stable salts of o-acetylsalicylic with basic amino acids amino acids HUP0302053A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10034802A DE10034802A1 (de) 2000-07-18 2000-07-18 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
PCT/EP2001/007669 WO2002005782A2 (de) 2000-07-18 2001-07-05 Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren

Publications (2)

Publication Number Publication Date
HUP0302053A2 HUP0302053A2 (hu) 2003-09-29
HUP0302053A3 true HUP0302053A3 (en) 2010-03-29

Family

ID=7649258

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302053A HUP0302053A3 (en) 2000-07-18 2001-07-05 Stable salts of o-acetylsalicylic with basic amino acids amino acids

Country Status (34)

Country Link
US (2) US6773724B2 (hu)
EP (1) EP1365737B1 (hu)
JP (2) JP2004507463A (hu)
KR (1) KR100773658B1 (hu)
CN (1) CN1205176C (hu)
AR (1) AR030305A1 (hu)
AT (1) ATE293589T1 (hu)
AU (2) AU2001278471B2 (hu)
BR (1) BR0112538A (hu)
CA (1) CA2416288C (hu)
CR (1) CR6888A (hu)
CZ (1) CZ300337B6 (hu)
DE (2) DE10034802A1 (hu)
DK (1) DK1365737T3 (hu)
EC (1) ECSP034437A (hu)
ES (1) ES2241849T3 (hu)
GT (1) GT200100134A (hu)
HK (1) HK1061811A1 (hu)
HR (1) HRP20030108B1 (hu)
HU (1) HUP0302053A3 (hu)
IL (2) IL153873A0 (hu)
MX (1) MXPA03000510A (hu)
MY (1) MY134521A (hu)
NO (1) NO20030222L (hu)
PE (1) PE20020267A1 (hu)
PL (1) PL204593B1 (hu)
PT (1) PT1365737E (hu)
RS (1) RS50329B (hu)
SK (1) SK286162B6 (hu)
SV (1) SV2002000557A (hu)
TW (1) TWI299729B (hu)
UY (1) UY26841A1 (hu)
WO (1) WO2002005782A2 (hu)
ZA (1) ZA200300469B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
DE10202019A1 (de) * 2002-01-18 2003-07-24 Bayer Ag Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II
US8142810B2 (en) 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
ATE442352T1 (de) * 2003-05-16 2009-09-15 Cephalon France Verfahren zur herstellung von modafinil
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US20060166901A1 (en) * 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
EP2610242A1 (en) 2006-07-09 2013-07-03 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
US9371284B2 (en) 2007-06-04 2016-06-21 Techfields Pharma Co., Ltd. Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses
DE102008004386A1 (de) * 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
CN101314029B (zh) * 2008-06-18 2010-12-08 四川省农业科学院实验场 乙酰水杨酸肽及其制备方法
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
KR20230085223A (ko) 2008-12-04 2023-06-13 충시 위 고투과력을 가진 조성물 및 이의 적용
JP5706409B2 (ja) * 2009-06-25 2015-04-22 テトラ,エスイーアー 新規なサリチル酸塩
CN101633624B (zh) * 2009-08-04 2013-05-01 蚌埠丰原医药科技发展有限公司 改进的赖氨匹林的制备方法
FR2965261B1 (fr) * 2009-09-30 2012-10-26 Holis Technologies Procede de preparation d'un sel d'acide o-acetylsalicylique d'un acide amine basique et composition obtenue par ce procede
FR2950625B1 (fr) * 2009-09-30 2016-12-02 Holis Tech Procede de preparation d'un sel d'acide o-acetylsalicylique d'un acide amine basique et composition obtenue
FR2973370B1 (fr) * 2011-03-29 2013-05-03 Holis Technologies Procede a faible cout pour la preparation d'un acide o-acetylsalicyclique et d'un acide amine basique
CN102503845A (zh) * 2011-09-28 2012-06-20 广州普星药业有限公司 一种dl-赖氨酸阿司匹林盐的制备方法及其应用
KR102309973B1 (ko) 2012-05-16 2021-10-06 테크필즈 파마 코., 엘티디. 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
CN102976962B (zh) * 2012-11-20 2015-02-04 南京工业大学 L-鸟氨酸阿司匹林复盐及其制备方法和应用
FR3021654B1 (fr) 2014-05-28 2016-06-24 Unither Pharmaceuticals Procede de preparation d'un sel d'acide acetylsalicylique et d'un acide amine basique
RU2764573C2 (ru) * 2016-12-23 2022-01-18 АспиЭйр ГмбХ Улучшенный синтез частиц ацетилсалицилата лизина ⋅ глицина
WO2018222583A1 (en) * 2017-05-30 2018-12-06 Rho Pharmaceuticals, Llc In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin)
WO2019026992A1 (ja) * 2017-08-03 2019-02-07 参天製薬株式会社 クロルヘキシジンを含有する医薬組成物
CN113105326A (zh) * 2021-03-24 2021-07-13 海南卓华制药有限公司 赖氨匹林的制备方法及应用
CN114478287A (zh) * 2021-12-31 2022-05-13 蚌埠丰原医药科技发展有限公司 一种赖氨匹林晶型及制备方法和应用
WO2023131645A1 (en) 2022-01-05 2023-07-13 Aspiair Gmbh Improved synthesis of lysine acetylsalicylate · glycine particles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2115060A1 (en) * 1970-11-26 1972-07-07 Metabio Freeze-dried acetylsalicylates of lysine and arginine - easily prepd derivs of aspirin
ES388158A1 (es) * 1971-02-11 1974-03-16 Liade Sa Lab Procedimiento de obtencion de sales solubles del acido ace-til salicilico.
JPS4856815A (hu) * 1971-11-13 1973-08-09
JPS55127345A (en) * 1979-03-23 1980-10-02 Kyowa Hakko Kogyo Co Ltd Preparation of acetylsalicylic acid salt
JPS5610110A (en) * 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
JPS56113741A (en) * 1980-02-13 1981-09-07 Mitsui Toatsu Chem Inc Preparation of crystal of acetylsalicylic acid salt
JPS5721345A (en) * 1980-07-15 1982-02-04 Mitsui Toatsu Chem Inc Purification of acetylsalicylate salt
CS247688B1 (cs) * 1984-12-22 1987-01-15 Evzen Kasafirek Způsob výroby soli lysinu s kyselinou acetylsalicylovou
JPS632929A (ja) * 1986-06-20 1988-01-07 Kao Corp アセチルサリチル酸製剤
EP0499142A3 (en) * 1991-02-09 1993-05-05 Hoechst Aktiengesellschaft Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs
DE4332093C2 (de) * 1993-09-22 1995-07-13 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Acetylsalicylsäure und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
ES2241849T3 (es) 2005-11-01
BR0112538A (pt) 2003-09-09
PL204593B1 (pl) 2010-01-29
CR6888A (es) 2004-10-28
DE50105985D1 (de) 2005-05-25
UY26841A1 (es) 2002-02-28
DK1365737T3 (da) 2005-07-11
IL153873A0 (en) 2003-07-31
NO20030222D0 (no) 2003-01-16
JP2004507463A (ja) 2004-03-11
CN1205176C (zh) 2005-06-08
AR030305A1 (es) 2003-08-20
EP1365737B1 (de) 2005-04-20
HRP20030108B1 (en) 2006-12-31
SV2002000557A (es) 2002-10-24
IL153873A (en) 2009-05-04
NO20030222L (no) 2003-01-16
SK672003A3 (en) 2003-06-03
US7449198B2 (en) 2008-11-11
RS50329B (sr) 2009-09-08
JP2012131824A (ja) 2012-07-12
CN1468209A (zh) 2004-01-14
CZ2003164A3 (cs) 2003-04-16
WO2002005782A3 (de) 2003-10-02
PL365648A1 (en) 2005-01-10
AU2001278471B2 (en) 2004-07-22
ECSP034437A (es) 2003-03-31
EP1365737A2 (de) 2003-12-03
AU7847101A (en) 2002-01-30
SK286162B6 (sk) 2008-04-07
CA2416288C (en) 2009-12-22
HRP20030108A2 (en) 2005-02-28
WO2002005782A2 (de) 2002-01-24
US6773724B2 (en) 2004-08-10
TWI299729B (en) 2008-08-11
CZ300337B6 (cs) 2009-04-22
PT1365737E (pt) 2005-08-31
MXPA03000510A (es) 2004-04-20
PE20020267A1 (es) 2002-06-08
KR20030019586A (ko) 2003-03-06
YU2003A (sh) 2006-08-17
US20020091108A1 (en) 2002-07-11
KR100773658B1 (ko) 2007-11-05
ZA200300469B (en) 2004-06-21
ATE293589T1 (de) 2005-05-15
HUP0302053A2 (hu) 2003-09-29
MY134521A (en) 2007-12-31
HK1061811A1 (en) 2004-10-08
CA2416288A1 (en) 2003-01-15
US20050009791A1 (en) 2005-01-13
DE10034802A1 (de) 2002-01-31
GT200100134A (es) 2002-03-22

Similar Documents

Publication Publication Date Title
IL153873A0 (en) Stable salts of o-acetylsalicylic with basic amino acids
AU2001278471A1 (en) Stable salts of o-acetylsalicyclic with basic amino acids
HUP0300299A3 (en) Composition comprising free amino acids
GB0018828D0 (en) Alkyl Amino Acid Derivatives useful as pharmaceutical agents
HK1080371A1 (en) Stable salts of o-acetylsalicylic acid containing basic amino acids ii
GB9907263D0 (en) Amino acid derivatives
HUP0001560A3 (en) Stable crystal salts of 5-methyl-tetrahydrofolic acid
HK1057539A1 (en) Beta-amino acid nitrile derivatives
AU2002224884A1 (en) Substituted anthranilic acids
IL153441A0 (en) Stable gabapentin having ph within a controlled range
PL361424A1 (en) ß-THIO-AMINO ACIDS
GB0024693D0 (en) Beta-amino acid cyclic carboxylic acids
AU3569801A (en) Amino acid derivatives and use thereof as nep, ace and ece inhibitors
PL357011A1 (en) Novel alpha-sulfin- and alpha-sulfonamino acid amide derivatives
AU2001258543A1 (en) Branched amino acids
GB0025386D0 (en) Branched amino acids
PL357715A1 (en) Alpha-sulfin- and alpha-sulfonamino acid amide derivatives
PL357012A1 (en) Novel alpha-sulfin- and alpha-sulfonamino acid amides
GB0017435D0 (en) 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
GB0027198D0 (en) Diastereomerically enriched amino acids
AUPQ896500A0 (en) Amino acid derivatives
GB0027024D0 (en) Substituted Phenyl-Cycloalkyl-Alkanoic acids compounds
SI1178958T1 (en) N-cyanomethyl amides as protease inhibitors
UA3783S (uk) Етикетка "азмол старт 2т"
HUP0204378A3 (en) A process for the preparation of salts of l-carnitine and alkanoyl l-carnitine with mucic acid

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE

FD9A Lapse of provisional protection due to non-payment of fees